Olink Holding AB
General Information | |
Business: | Our purpose is to enable and accelerate the field of proteomics by providing a platform of products and services, developed with key opinion leaders (KOLs), that are deployed across major biopharmaceutical companies and leading clinical and academic institutions, to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. Since our inception, we have served a customer base of approximately 630 customer accounts in over 40 countries worldwide. We support 30 of the world’s largest 40 biopharmaceutical companies by 2019 revenue, including all of the largest 19, and many leading academic institutions. |
Industry: | LABORATORY ANALYTICAL INSTRUMENTS |
Employees: | 214 |
Founded: | 2018 |
Contact Information | |
Address | Uppsala Science Park, SE-751 83, Uppsala, Sweden |
Phone Number | +46 (0) 18 - 444 39 70 |
Web Address | http://www.olink.com |
View Prospectus: | Olink Holding AB |
Financial Information | |
Market Cap | $2023mil |
Revenues | $54.1 mil (last 12 months) |
Net Income | $-6.8 mil (last 12 months) |
IPO Profile | |
Symbol | OLK |
Exchange | NASDAQ |
Shares (millions): | 17.7 |
Price range | $20.00 - $20.00 |
Est. $ Volume | $352.9 mil |
Manager / Joint Managers | Goldman Sachs/ Morgan Stanley/ SVB Leerink |
CO-Managers | BTIG |
Expected To Trade: | 3/25/2021 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |